Hypothesis

Daily supplementation with a single Lactobacillus strain that preferentially upregulates enterochromaffin cell tryptophan hydroxylase will produce a rapid, measurable increase in HRV (RMSSD and HF power) within 48 h, and the magnitude of this HRV shift will predict the subsequent reduction in self‑reported anxiety scores after 7 days of continuous dosing.

Mechanistic Rationale

The gut‑brain axis communicates via vagal afferents that sense microbial metabolites, especially serotonin derived from tryptophan. Certain Lactobacillus strains (e.g., L. plantarum LP‑28) enhance tryptophan availability and serotonin synthesis in the gut lumen [3]. Elevated luminal serotonin activates 5‑HT₃ receptors on vagal afferents, increasing nucleus tractus solitarius firing and thereby boosting parasympathetic outflow, which is reflected in higher HRV [5]. We propose that this serotonergic vagal drive is the earliest detectable signal of gut‑brain communication, preceding downstream hormonal changes (cortisol, GABA) that require longer exposure.

Individual variability in baseline microbiome composition determines the capacity of a given strain to modulate tryptophan pathways. Participants with low baseline tryptophan‑metabolizing potential will show a larger HRV response when supplemented with a strain that compensates for this deficit, creating a responder phenotype that can be identified pretrial via shotgun metagenomics.

Testable Predictions

1. Rapid HRV increase – Within 48 h of the first dose, RMSSD and HF power will rise significantly above baseline (paired t‑test, p < 0.01).
2. HRV‑anxiety coupling – The percent change in HRV at 48 h will correlate negatively with anxiety score change at day 7 (Pearson r < ‑0.5, p < 0.01).
3. Strain specificity – A control strain lacking tryptophan‑hydroxylase‑upregulating capacity will not produce the HRV increase or anxiety improvement.
4. Microbiome‑guided response – Baseline abundance of tryptophan‑producing taxa (e.g., certain Bacteroides spp.) will inversely predict HRV delta (linear regression, β < 0, p < 0.05).

Experimental Design (n=1 Citizen‑Science Protocol)

• Baseline (Day 0) – Collect fasting stool for shotgun metagenomics, record HRV overnight via chest strap (RMSSD, HF), and complete State‑Trait Anxiety Inventory (STAI‑S).
• Intervention (Days 1‑7) – Administer 5 × 10⁹ CFU/day of the test Lactobacillus strain in capsules, taken with breakfast. Continue normal diet, log any deviations.
• Monitoring – Record HRV each morning (5‑min supine) and evening; complete STAI‑S each evening.
• Washout & Crossover – After a 14‑day washout (confirmed by disappearance of strain from stool qPCR), repeat with the control strain.
• Analysis – Compute HRV delta (Day 2 – Day 0), anxiety delta (Day 7 – Day 0), and test predictions using paired comparisons.

Potential Confounds and Mitigations

• Sleep and activity – Influence HRV; control by maintaining consistent sleep‑wake times and logging exercise; include as covariates in regression.
• Dietary tryptophan – Variations could mask microbial effects; standardize breakfast macronutrients across the week.
• Placebo effect – Use blinded capsules and a control strain to isolate pharmacological from expectancy effects.

Falsifiability

If HRV does not rise within 48 h, or if HRV changes fail to predict anxiety improvement despite confirmed strain engraftment and tryptophan pathway upregulation (metabolomic stool assay), the hypothesis is falsified. Conversely, a consistent HRV‑anxiety coupling across multiple strains would strengthen the model and suggest a general biomarker for rapid gut‑brain signaling.

By linking strain‑specific microbial enzymology to real‑time vagal output, this approach refines psychobiotic selection from population averages to individualized, mechanism‑driven prescriptions.